¹Khwarizmi Institute of science and technology, Qeshm island, Hormozgan, Iran

²Congress 60 Non-governmental organization

*Corresponding Author: Arvin Haghighatfard, Khwarizmi Institute of science and technology, Qesh island, Hormozgan, Iran; Email: [email protected]

Received Date: August 16, 2023 

Published Date:  September 11, 2023 

Citation: Dezhakam H, et al. (2023). Novel Protocol of Opium Tincture Oral Usage in Two Cases with Chronic Myeloid Leukemia and Hodgkin Lymphoma. Mathews J Gastroenterol Hepatol. 8(2):21. 

Copyrights: Dezhakam H, et al. © (2023). 

ABSTRACT

We report two cases of chronic myeloid leukemia (CML). The first patient was a 40-year-old man who presented with a prolonged history of upper abdominal discomfort, anorexia, and with fever. Examination revealed moderate hepatosplenomegaly. Examinations showed that he was found to have leucocytosis with moderate anemia. Given the leucocytosis, he was investigated for CML and found to be positive for BCR-ABL by Real-time PCR. He received imatinib 400 mg/day and achieved a complete hematological response at the end of 3 months. The second patient was a 40-year-old male diagnosed with Hodgkin lymphoma based on a Lymph node biopsy. He completed five cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy. Both patients were previously addicted to opium and before the cancer diagnosis, these patients were successfully treated for their addiction with a new method of using opium tincture called Dezhakam step time (DST). After the diagnosis of cancer, both patients were treated with opium tincture using a new protocol of taper up-off that took about 11 months. Both patients showed significant clinical improvement along with a dramatic reduction of pain and no craving or dependence symptoms during and after the treatment.

Keywords: Opium tincture, Chronic myeloid leukemia, Hodgkin lymphoma

ABBREVIATIONS

CML: Chronic myeloid leukemia

OUD: opioid use disorder

DST: Dezhakam step time